Cargando…

Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling

Osimertinib, a 3rd generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the first-line standard-of-care for EGFR-mutant non-small cell lung cancer (NSCLC) patients, while acquired drug resistance will inevitably occur. Interleukin-6 (IL-6) is a keystone cytokine in in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Li, Li, Zhujun, Lu, Conghua, Li, Jianghua, Zhang, Kejun, Lin, Caiyu, Tang, Xiaolin, Liu, Zhulin, Zhang, Yimin, Han, Rui, Wang, Yubo, Feng, Mingxia, Zhuang, Yuan, Hu, Chen, He, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866396/ https://www.ncbi.nlm.nih.gov/pubmed/35197546 http://dx.doi.org/10.1038/s42003-022-03111-7

Ejemplares similares

Aspirin sensitizes osimertinib‐resistant NSCLC cells in vitro and in vivo via Bim‐dependent apoptosis induction
por: Han, Rui, et al.
Publicado: (2020)

The potential therapeutic regimen for overcoming resistance to osimertinib due to rare mutations in NSCLC
por: Han, Rui, et al.
Publicado: (2023)

Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway
por: Li, Li, et al.
Publicado: (2016)

Metformin Combining PD-1 Inhibitor Enhanced Anti-Tumor Efficacy in STK11 Mutant Lung Cancer Through AXIN-1-Dependent Inhibition of STING Ubiquitination
por: Wang, Zhiguo, et al.
Publicado: (2022)

First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments
por: Nie, Naifu, et al.
Publicado: (2022)

Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway
por: Li, Li, et al.
Publicado: (2015)

Microenvironmental stiffness mediates cytoskeleton re-organization in chondrocytes through laminin-FAK mechanotransduction
por: Zhou, Chenchen, et al.
Publicado: (2022)

Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1
por: Chen, Hengyi, et al.
Publicado: (2020)

Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR‐TKI treatment in advanced non‐small cell lung cancer
por: Zheng, Jie, et al.
Publicado: (2022)

Laminin promotes differentiation of rat embryonic stem cells into cardiomyocytes by activating the integrin/FAK/PI3K p85 pathway
por: Wang, Duo, et al.
Publicado: (2019)

Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines
por: Huanwen, Wu, et al.
Publicado: (2009)

Monocyte-to-macrophage switch reversibly impaired by Ibrutinib
por: Ferrarini, Isacco, et al.
Publicado: (2019)

pH-responsive theranostic nanoplatform of ferrite and ceria co-engineered nanoparticles for anti-inflammatory
por: Dou, Yuanyao, et al.
Publicado: (2022)

Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction
por: Chen, Hengyi, et al.
Publicado: (2017)

Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
por: Lin, Caiyu, et al.
Publicado: (2021)

The direct effect of Focal Adhesion Kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis
por: Golubovskaya, Vita M, et al.
Publicado: (2009)

Caveolin-1-mediated STAT3 activation determines electrotaxis of human lung cancer cells
por: Li, Li, et al.
Publicado: (2017)

Correction: Caveolin-1-mediated STAT3 activation determines electrotaxis of human lung cancer cells
por: Li, Li, et al.
Publicado: (2018)

Reversible Systolic Heart Failure in a Patient on Ibrutinib Chemotherapy
por: Khaja, Misbahuddin, et al.
Publicado: (2022)

Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib
por: Bye, Alexander P., et al.
Publicado: (2022)

Biological Significance of (18)F-FDG PET/CT Maximum Standard Uptake Value for Predicting EGFR Mutation Status in Non-Small Cell Lung Cancer Patients
por: Wang, Yubo, et al.
Publicado: (2021)

TAPO in first‐line osimertinib therapy and continuation of osimertinib
por: Mimura, Chihiro, et al.
Publicado: (2022)

Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis
por: Huang, Fangmin, et al.
Publicado: (2023)

Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP signaling
por: Gao, Jiaming, et al.
Publicado: (2023)

Genotyping of cerebrospinal fluid in lung cancer patients with leptomeningeal metastasis
por: Nie, Naifu, et al.
Publicado: (2022)

Ibrutinib-induced cardiomyopathy
por: Kyi, Htay Htay, et al.
Publicado: (2019)

Extrahepatic metabolism of ibrutinib
por: Rood, Johannes J. M., et al.
Publicado: (2020)

CPNE3 promotes migration and invasion in non-small cell lung cancer by interacting with RACK1 via FAK signaling activation
por: Lin, Hechun, et al.
Publicado: (2018)

Laminin Isoforms and Laminin-Producing Cells in Rat Anterior Pituitary
por: Ramadhani, Dini, et al.
Publicado: (2012)

A Luminacin D Analog HL142 Inhibits Ovarian Tumor Growth and Metastasis by Reversing EMT and Attenuating the TGFβ and FAK Pathways
por: Wang, Baojin, et al.
Publicado: (2021)

Drug repurposing: Ibrutinib exhibits immunosuppressive potential in organ transplantation
por: Zhang, Qing, et al.
Publicado: (2018)

Effective clinical response of lung adenocarcinoma harboring EGFR 19Del/T790M/in cis-C797S osimertinib to osimertinib and gefitinib combination therapy
por: Wang, Yanyan, et al.
Publicado: (2023)

Backtracking on FAK
por: Leslie, Mitch
Publicado: (2008)

FAK monitoring
por: Metzmacher, K D
Publicado: (1974)

A peptide derived from laminin-γ3 reversibly impairs spermatogenesis in rats
por: Su, Linlin, et al.
Publicado: (2012)

Case Report: Mucous Membrane Pemphigoid With IgG and IgA Anti-Laminin γ1 Antibodies and IgA Anti-Laminin α5 Antibodies
por: Kuang, Wenjing, et al.
Publicado: (2022)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

Osimertinib-Induced Cardiomyopathy
por: Patel, Shruti R., et al.
Publicado: (2020)

Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis
por: Wang, Chunsheng, et al.
Publicado: (2023)

Interactions of the 67 kDa laminin receptor and its precursor with laminin
por: Fatehullah, Aliya, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ah4rs8cfvc7q7of6d9vungf8d0